HP and lymphoma: OAML is a rare indolent lymphoma, for its treatment no consensus is available because no prospective clinical trials have been conducted to define the optimal treatment approach for these patients.133 However, patients managed by a watch & wait for approach have a 10-years OS of 94%.118 Moreover, limited toxicity and costs associated with antibiotic treatment should suggest the opportunity to target the possibly correlated infection by C. psittaci, in analogy with gastric MALT lymphoma and Hp eradication.